Toripalimab (PDCD1/PD1/CD279) - Research Grade Biosimilar

Toripalimab is humanized monoclonal antibody targeted at programmed death receptor 1 (PD-1), used to treat patients with unresectable or metastatic melanoma who have failed previous systemic system therapy, and is intended for treatment Breast cancer, lymphoma, malignant melanoma, urogenital cancer and other types of solid tumors.

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.